-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The reporter was informed on the 19th that the Chinese original innovative drug Nerlik ® was first launched in the world.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The national "Major New Drug Creation" special results release and the world's first listing conference of Orebatinib (Nelic®) hosted by the China Pharmaceutical Innovation Promotion Association were held online and offline
.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
Chen Kaixian, academician of the Chinese Academy of Sciences and deputy chief technical engineer of major new drug creation, said in an interview with reporters on the 19th: "Nelic® is China's third-generation BCR-ABL inhibitor, which effectively solves China's drug-resistant chronic myelogenous leukemia.
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
Chen Kaixian said that as a new drug supported by a major national special project, Nerlik® represents the strength of China’s original and innovative drugs, and is the highlight and pride of the implementation of major special projects; and the launch of Nerlik® fully demonstrates the innovative level of Chinese local medicines .
Encourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
Encourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
It is reported that chronic myeloid leukemia (CML) is a malignant tumor related to white blood cells
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
Professor Huang Xiaojun , the principal investigator of the Chinese clinical trial of Nelek® , the director of the Institute of Hematology of Peking University, and the director of the Department of Hematology of Peking University People’s Hospital , said: The clinical treatment of drug-resistant chronic myeloid leukemia has great potential in the field of clinical treatment, and it is very hopeful that it will become a'Best-in-Class' drug in this field
.
" The expert said that he is very happy to witness the successful launch of Nelica®, which means The original drug resistance dilemma of CML treatment in China has been broken, and a brand-new milestone drug has been ushered in, which is of great significance to clinicians and patients
.
.
" The expert said that he is very happy to witness the successful launch of Nelica®, which means The original drug resistance dilemma of CML treatment in China has been broken, and a brand-new milestone drug has been ushered in, which is of great significance to clinicians and patients
.
At the launch meeting, Professor Jiang Qian, the main investigator of the Chinese clinical trial of Nerlik® and the deputy director of the Department of Hematology, Peking University People's Hospital, introduced and interpreted the key clinical data of Nerlik®
.
She said: "I hope the drug will benefit more patients
.
"
.
She said: "I hope the drug will benefit more patients
.
"
It is understood that Nallik® is a new drug developed by Guangzhou Shunjian Biomedical Technology Co.
, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, said: "Yasheng Pharmaceuticals has made solid efforts in research and development for many years and has made great progress in innovation, industrialization and internationalization in recent years.
Consistent
.
I hope that in the future, there will be more and more local Chinese pharmaceutical innovation companies like Yasheng Pharmaceuticals, helping China to transform from a major pharmaceutical country to a powerful pharmaceutical country, and contribute to the health of people in China and the world
.
"
, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, said: "Yasheng Pharmaceuticals has made solid efforts in research and development for many years and has made great progress in innovation, industrialization and internationalization in recent years.
Consistent
.
I hope that in the future, there will be more and more local Chinese pharmaceutical innovation companies like Yasheng Pharmaceuticals, helping China to transform from a major pharmaceutical country to a powerful pharmaceutical country, and contribute to the health of people in China and the world
.
"
Dr.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
During the interview, the reporter learned that the "National Hematological Diseases Clinical Medicine Research Center Yasheng Research Institute" was officially inaugurated
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
The reporter was informed on the 19th that the Chinese original innovative drug Nerlik ® was first launched in the world.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The national "Major New Drug Creation" special results release and the world's first listing conference of Orebatinib (Nelic®) hosted by the China Pharmaceutical Innovation Promotion Association were held online and offline
.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
Chen Kaixian, academician of the Chinese Academy of Sciences and deputy chief technical engineer of major new drug creation, said in an interview with reporters on the 19th: "Nelic® is China's third-generation BCR-ABL inhibitor, which effectively solves China's drug-resistant chronic myelogenous leukemia.
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
Chen Kaixian said that as a new drug supported by a major national special project, Nerlik® represents the strength of China’s original and innovative drugs, and is the highlight and pride of the implementation of major special projects; and the launch of Nerlik® fully demonstrates the innovative level of Chinese local medicines .
Encourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
Encourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
It is reported that chronic myeloid leukemia (CML) is a malignant tumor related to white blood cells
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
®、、：“，®，‘Best-in-Class’
。”，®，CML，，
。
。”，®，CML，，
。
，®、®
。：“
。”
。：“
。”
，®
。：“、，、、，
。，，，
。”
。：“、，、、，
。，，，
。”
Dr.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
During the interview, the reporter learned that the "National Hematological Diseases Clinical Medicine Research Center Yasheng Research Institute" was officially inaugurated
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
The reporter was informed on the 19th that the Chinese original innovative drug Nerlik ® was first launched in the world.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The drug is used to treat chronic myelogenous leukemia (CML) in adult patients with drug resistance
.
The national "Major New Drug Creation" special results release and the world's first listing conference of Orebatinib (Nelic®) hosted by the China Pharmaceutical Innovation Promotion Association were held online and offline
.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
Medicine, medicine, medicine.
Previously, Nellyc® received marketing approval from the National Medical Products Administration (NMPA) of China , opening a new chapter in the precision treatment of chronic myeloid leukemia (CML)
.
Chen Kaixian, academician of the Chinese Academy of Sciences and deputy chief technical engineer of major new drug creation, said in an interview with reporters on the 19th: "Nelic® is China's third-generation BCR-ABL inhibitor, which effectively solves China's drug-resistant chronic myelogenous leukemia.
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
The major social problem that patients have no medicine to cure has filled the domestic gap in clinically urgently needed products
.
"
Chen Kaixian said that as a new drug supported by a major national special project, Nerlik® represents the strength of China’s original and innovative drugs, and is the highlight and pride of the implementation of major special projects; and the launch of Nerlik® fully demonstrates the innovative level of Chinese local medicines .
Encourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseEncourage more pharmaceutical companies to devote themselves to the research and development of innovative drugs, continuously improve China's pharmaceutical R&D and innovation capabilities, and help achieve the goal of "Healthy China 2030"
.
It is reported that chronic myeloid leukemia (CML) is a malignant tumor related to white blood cells
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
.
Today, CML has changed from an incurable disease to a "special chronic disease" like hypertension and diabetes
.
However, acquired drug resistance has always been the main challenge for CML treatment, and some patients will cause disease progression or even death due to drug resistance
.
Among them, the T315I mutation is one of the common types of drug-resistant mutations, and patients are resistant to all current first- and second-generation related inhibitors
.
It is understood that before the approval of Nalike® for marketing, Chinese patients with T315I mutation-resistant CML have long faced the dilemma of no cure
.
Professor Huang Xiaojun , the principal investigator of the Chinese clinical trial of Nelek® , the director of the Institute of Hematology of Peking University, and the director of the Department of Hematology of Peking University People’s Hospital , said: The clinical treatment of drug-resistant chronic myeloid leukemia has great potential in the field of clinical treatment, and it is very hopeful that it will become a'Best-in-Class' drug in this field
.
" The expert said that he is very happy to witness the successful launch of Nelica®, which means The original drug resistance dilemma of CML treatment in China has been broken, and a brand-new milestone drug has been ushered in, which is of great significance to clinicians and patients
.
Hospital hospital hospital.
" The expert said that he is very happy to witness the successful launch of Nelica®, which means The original drug resistance dilemma of CML treatment in China has been broken, and a brand-new milestone drug has been ushered in, which is of great significance to clinicians and patients
.
At the launch meeting, Professor Jiang Qian, the main investigator of the Chinese clinical trial of Nerlik® and the deputy director of the Department of Hematology, Peking University People's Hospital, introduced and interpreted the key clinical data of Nerlik®
.
She said: "I hope the drug will benefit more patients
.
"
.
She said: "I hope the drug will benefit more patients
.
"
It is understood that Nallik® is a new drug developed by Guangzhou Shunjian Biomedical Technology Co.
, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, said: "Yasheng Pharmaceuticals has made solid efforts in research and development for many years and has made great progress in innovation, industrialization and internationalization in recent years.
Consistent
.
I hope that in the future, there will be more and more local Chinese pharmaceutical innovation companies like Yasheng Pharmaceuticals, helping China to transform from a major pharmaceutical country to a powerful pharmaceutical country, and contribute to the health of people in China and the world
.
"
Healthy, healthy, healthy, Ltd.
, a wholly-owned subsidiary of Yasheng Pharmaceutical
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, said: "Yasheng Pharmaceuticals has made solid efforts in research and development for many years and has made great progress in innovation, industrialization and internationalization in recent years.
Consistent
.
I hope that in the future, there will be more and more local Chinese pharmaceutical innovation companies like Yasheng Pharmaceuticals, helping China to transform from a major pharmaceutical country to a powerful pharmaceutical country, and contribute to the health of people in China and the world
.
"
Dr.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
Yifan Zhai, Chief Medical Officer of Ascent Pharmaceuticals and President and CEO of Shunjian Pharmaceuticals, told reporters: "During the development of Nelek®, R&D personnel have always adhered to international standards
.
Nelek® has become one of the few self-supporting projects.
On the implementation of the global R&D strategy for the original Chinese original innovative drugs
.
” According to reports, based on the excellent clinical effectiveness and safety of Nerlik®, it has successively obtained the orphan drug qualification and the rapid review qualification of the US FDA; and obtained the international blood Widely recognized by the academic community
.
Zhai Yifan hopes that, in the near future, Nerlik®, a Chinese-original and world-leading innovative drug, can benefit more global patients
.
During the interview, the reporter learned that the "National Hematological Diseases Clinical Medicine Research Center Yasheng Research Institute" was officially inaugurated
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
.
The Institute will focus on the field of hematological tumors, covering functions such as basic tumor research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation
.
(Finish)
